생체 치료제 제품 및 미생물 CDMO 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 용도별, 제품별, 제제 유형별, 규모별, 지역별＆경쟁(2021-2031년)
Live Biotherapeutics Products and Microbe CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application, By Product, By Type of Formulation, By Scale of Operation, By Region & Competition, 2021-2031F
상품코드:1953431
리서치사:TechSci Research
발행일:2026년 01월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 생체 치료제 제품 및 미생물 CDMO 시장은 2025년 332억 2,000만 달러에서 2031년까지 2,265억 6,000만 달러로 급성장하여 CAGR37.71%로 확대될 것으로 예측됩니다. 생수처리제(LBPs)는 살아있는 미생물을 이용하여 질병을 치료하거나 예방하기 때문에 복잡한 혐기성 발효 및 제제화에 대응할 수 있는 전문 위탁개발제조기관(CDMO)이 필요합니다. 시장 가속화는 임상 파이프라인의 강화와 바이오 제약사들이 대규모 자본 투자 없이 제조의 복잡성을 극복하기 위해 외부 파트너를 활용하는 추세에 의해 촉진되고 있습니다. 또한, 공공 부문의 노력도 이 분야를 적극적으로 추진하고 있습니다. 예를 들어, Human Microbiome Action은 2025년 유럽위원회가 Horizon Europe을 통해 마이크로바이옴 기반 솔루션의 개발 및 배포를 촉진하기 위해 약 1억 유로를 할당했다고 보고했습니다.
시장 개요
예측 기간
2027-2031년
시장 규모 : 2025년
332억 2,000만 달러
시장 규모 : 2031년
2,265억 6,000만 달러
CAGR : 2026-2031년
37.71%
가장 성장이 빠른 부문
임상 규모 운영
최대 시장
북미
그러나 전 세계적으로 통일된 규제 기준이 존재하지 않는 것은 시장 발전에 큰 걸림돌이 되고 있습니다. 이러한 규제 측면의 불투명성은 표준화된 제조 프로토콜과 품질 관리 시스템 구축을 복잡하게 만들고, 임상시험에서 상업적 규모의 생산으로 원활하게 전환하는 것을 방해하고 있습니다. 결국, 이러한 불확실성은 신제품 승인 과정을 지연시키고, 새로운 치료법이 시장에 출시되는 속도를 제한할 수 있습니다.
시장 성장 촉진요인
시장 성장의 주요 촉매제는 세계 바이오 치료제 임상 파이프라인의 급속한 확장으로, 복잡한 혐기성 제조 작업을 확장할 수 있는 CDMO(위탁 개발 및 제조 기관)에 대한 중요한 니즈를 창출하고 있습니다. 후보물질이 초기 발견 단계에서 후기 임상시험으로 진행됨에 따라, 고품질의 GMP를 준수하는 임상시험용 물질에 대한 수요가 크게 증가함에 따라 개발사들은 외부 제조 자원을 활용해야 하는 상황에 처해 있습니다. 이러한 성숙도는 Vedanta Biosciences(2024년 5월, 경구용 박테리아 컨소시엄을 이용한 임상 3상 'RESTORATiVE303'의 첫 환자 등록을 발표)와 같은 선진적인 시험 단계로 전환하는 기업들에 의해 두드러지게 나타나고 있습니다.
또한, 마이크로바이옴 치료에 대한 자본 투자 및 자금 조달 증가는 전문 시설의 건설과 안정성 향상 제제 기술 개발에 필요한 유동성을 제공함으로써 이 분야를 촉진하고 있습니다. 이러한 자금 지원은 바이오기술의 혁신을 촉진할 뿐만 아니라 시장의 상업적 타당성을 뒷받침하고, 기업이 과도한 인프라 비용을 부담하지 않고 생산을 아웃소싱할 수 있게 해줍니다. 예를 들어, 엔테로바이오틱스는 2024년 4월 임상 파이프라인과 제조 역량 강화를 위해 2,700만 파운드의 자금 조달을 확보했다고 발표했습니다. 또한, 상업적 성공은 전략적 활동을 촉진합니다. 2024년 세레스 테라퓨틱스가 VOWST 자산을 네슬레헬스사이언스에 1억 5,500만 달러의 선불금을 받고 매각한 사례에서 알 수 있듯이, 상업화를 통해 얻을 수 있는 가치를 강조하고 있습니다.
시장의 과제
세계 바이오치료제 및 미생물 CDMO 시장에는 세계 규제 기준의 부재가 큰 장벽으로 작용하고 있습니다. 이러한 단편적인 규제는 개발자와 수탁 제조업체 모두에게 심각한 불확실성을 야기하고 있으며, 각 지역마다 서로 다른 규정 준수 요건을 관리해야 하는 상황을 초래하고 있습니다. 생물학적 치료 제품은 복잡한 생물학적 유기체에 의존하기 때문에 통일된 프레임워크의 부재로 인해 제조 공정과 분석 방법의 검증이 점점 더 어려워지고 CDMO가 표준 프로토콜을 확립하는 데 어려움을 겪게 됩니다. 이로 인해 운영 비용이 증가하고, 기술 이전 및 스케일업의 타임라인이 길어질 수 있습니다.
결과적으로, 이러한 불확실한 규제 환경은 탄탄한 임상 파이프라인이 시장성 있는 치료제로 발전하는 것을 방해하고 있습니다. 임상시험에서 대량 생산으로 확장하는 과정에서 기업은 심각한 위험에 직면하게 됩니다. 일관성 없는 가이드라인으로 인해 지역마다 다른 요구 사항을 충족시키기 위해 비용이 많이 드는 프로세스를 재설계해야 하는 경우가 많기 때문입니다. 이러한 병목현상의 심각성은 혁신을 승인된 치료제로 전환하는 것이 얼마나 어려운지를 보면 알 수 있습니다. Alliance for Regenerative Medicine의 2025년 데이터에 따르면, 첨단 치료 분야에서 전 세계 매출의 약 75%가 10종 미만의 시판 제품에서 창출되고 있으며, 이는 국제적인 일관성 부족으로 인해 광범위한 상업적 성공이 제한되고 있음을 보여줍니다. 어떻게 제한하고 있는지를 보여줍니다.
시장 동향
현재 시장은 통합형 엔드-투-엔드 서비스 모델의 보급으로 재편되고 있습니다. CDMO(위탁개발제조기관)가 역량을 통합하여 균주 분리부터 상업적 충전 및 포장에 이르는 제품 수명주기 전반을 관리하는 형태입니다. 이러한 진화는 복잡한 공급망을 간소화하고 민감한 혐기성 생물학적 물질을 서로 다른 공급업체 간에 옮기는 데 따른 위험을 최소화해야 할 필요성에 의해 추진되고 있습니다. 통합된 개발 및 제조 서비스를 제공함으로써 공급자는 타임라인을 단축하고 일관성을 확보할 수 있습니다. 예를 들어, 바이오즈 인더스트리는 2024년 12월 보고서에서 600종 이상의 박테리아 균주를 생산하고 전 세계에 1,000만 개의 완제품을 납품했다고 밝혔는데, 이는 이 통합 전략이 얼마나 큰 규모인지 잘 보여줍니다.
동시에 유전자 조작 생수처리제(eLBP)의 출현은 특정 치료 효과를 가진 변형된 생물체를 관리하기 위한 고도로 전문화된 제조 기술에 대한 수요를 자극하고 있습니다. 기존 컨소시엄과 달리, 이러한 차세대 치료법은 고도의 유전자 편집 도구와 엄격한 봉쇄 프로토콜이 필요하며, CDMO(위탁개발생산기관)에 새로운 처리 기술을 도입하도록 요구하고 있습니다. 이러한 기술적 진보는 특정 질병 경로를 표적으로 삼는 정밀한 미생물군집의 변형이 가능하며, 그 잠재력은 2024년 7월 Eligo Bioscience가 Nature지에 발표한 획기적인 연구를 통해 입증되었습니다. 이 연구는 장내 환경에서 박테리아를 거의 완벽한 효율로 직접 유전자 변형하는 능력을 보여주었습니다.
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 생체 치료제 제품 및 미생물 CDMO 시장 전망
제6장 북미의 생체 치료제 제품 및 미생물 CDMO 시장 전망
제7장 유럽의 생체 치료제 제품 및 미생물 CDMO 시장 전망
제8장 아시아태평양의 생체 치료제 제품 및 미생물 CDMO 시장 전망
제9장 중동 및 아프리카의 생체 치료제 제품 및 미생물 CDMO 시장 전망
제10장 남미의 생체 치료제 제품 및 미생물 CDMO 시장 전망
제11장 시장 역학
제12장 시장 동향과 발전
제13장 세계의 생체 치료제 제품 및 미생물 CDMO 시장 : SWOT 분석
제14장 Porter의 Five Forces 분석
제15장 경쟁 구도
제16장 전략적 제안
제17장 회사 소개 및 면책조항
LSH
영문 목차
영문목차
The Global Live Biotherapeutics Products and Microbe CDMO Market is projected to surge from USD 33.22 Billion in 2025 to USD 226.56 Billion by 2031, expanding at a CAGR of 37.71%. Because Live Biotherapeutic Products (LBPs) utilize live microorganisms to treat or prevent diseases, they require specialized Contract Development and Manufacturing Organizations (CDMOs) equipped to handle intricate anaerobic fermentation and formulation tasks. Market acceleration is fueled by a strengthening clinical pipeline and the tendency of biopharmaceutical firms to utilize external partners to navigate manufacturing complexities without significant capital expenditure. Furthermore, public sector initiatives are actively promoting this sector; for instance, Human Microbiome Action noted in 2025 that the European Commission allocated nearly €100 million through Horizon Europe to foster development and deployment of microbiome-based solutions.
Market Overview
Forecast Period
2027-2031
Market Size 2025
USD 33.22 Billion
Market Size 2031
USD 226.56 Billion
CAGR 2026-2031
37.71%
Fastest Growing Segment
Clinical Scale Operations
Largest Market
North America
However, the absence of harmonized global regulatory standards serves as a significant obstacle to market progress. This regulatory ambiguity complicates the creation of standardized manufacturing protocols and quality control systems, which hinders the smooth transition from clinical trials to commercial-scale production. Ultimately, these uncertainties can decelerate the approval process for new products, limiting the speed at which novel therapies reach the market.
Market Driver
A primary catalyst for market growth is the swift broadening of the global live biotherapeutic clinical pipeline, creating a critical need for CDMOs that can scale complex anaerobic manufacturing operations. As candidates advance from early discovery phases to late-stage pivotal trials, the requirement for high-quality, GMP-compliant clinical trial materials increases substantially, prompting developers to engage external manufacturing resources. This maturation is highlighted by companies entering advanced testing stages, such as Vedanta Biosciences, which announced in May 2024 that it had enrolled the first patient in its pivotal Phase 3 RESTORATiVE303 study for an orally administered bacterial consortium.
Additionally, rising capital investments and funding for microbiome-based therapies are driving the sector forward by providing necessary liquidity for building specialized facilities and improving stability-enhancing formulation technologies. This financial support not only fuels biotech innovation but also confirms the commercial viability of the market, enabling firms to outsource production without bearing prohibitive infrastructure costs. For example, EnteroBiotix announced in April 2024 that it had secured £27 million to further its clinical pipeline and manufacturing capabilities. Furthermore, commercial success drives strategic activity, as seen in 2024 when Seres Therapeutics sold its VOWST assets to Nestle Health Science for an upfront payment of $155 million, highlighting the value realized upon commercialization.
Market Challenge
The lack of harmonized global regulatory standards constitutes a major hurdle for the Global Live Biotherapeutics Products and Microbe CDMO Market. This regulatory fragmentation fosters deep uncertainty for both developers and contract manufacturers, who are forced to manage differing compliance mandates across various regions. Since live biotherapeutic products rely on complex biological organisms, the lack of a unified framework makes validating manufacturing processes and analytical methods increasingly difficult, causing CDMOs to struggle with establishing standard protocols, which raises operational costs and prolongs timelines for technology transfer and scaling.
Consequently, this uncertain regulatory landscape hampers the movement of a robust clinical pipeline toward becoming marketable therapies. Companies encounter significant risks when scaling from clinical trials to mass production, as inconsistent guidelines often demand costly process re-engineering to satisfy divergent regional requirements. The severity of these bottlenecks is illustrated by the difficulty in transforming innovation into approved treatments; according to the Alliance for Regenerative Medicine in 2025, roughly 75 percent of global revenue in the advanced therapy sector came from fewer than ten commercialized products, highlighting how a lack of international alignment restricts broader commercial success.
Market Trends
The market is currently being reshaped by the proliferation of integrated end-to-end service models, where CDMOs consolidate their capabilities to manage the full product lifecycle, spanning from strain isolation to commercial fill-finish. This evolution is motivated by the necessity to simplify complex supply chains and minimize risks involved in transferring sensitive anaerobic biological materials between different vendors. By providing unified development and manufacturing services, providers can hasten timelines and ensure consistency; for instance, Biose Industrie noted in its December 2024 report that it had manufactured over 600 bacterial strains and delivered 10 million finished products worldwide, showcasing the scale of this integrated strategy.
Concurrently, the emergence of genetically engineered live biotherapeutics (eLBPs) is stimulating demand for highly specialized manufacturing technologies designed to manage modified organisms with specific therapeutic payloads. Unlike traditional consortia, these next-generation treatments necessitate advanced genetic editing tools and strict containment protocols, compelling CDMOs to implement novel processing techniques. This technical progression enables precise microbiome modification to target specific disease pathways, a potential validated by Eligo Bioscience in July 2024 when they announced a landmark study in Nature demonstrating the ability to genetically modify bacteria directly within the gut environment with near-perfect efficiency.
Key Market Players
Lonza Group Ltd.
Catalent, Inc.
Thermo Fisher Scientific Inc.
FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
Samsung Biologics Co., Ltd.
Recipharm AB
Eurofins Scientific SE
AGC Biologics A/S
Boehringer Ingelheim International GmbH
Piramal Pharma Limited
Report Scope
In this report, the Global Live Biotherapeutics Products and Microbe CDMO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Live Biotherapeutics Products and Microbe CDMO Market, By Application
C.difficle
Crohns disease
IBS
Diabetes
Others
Live Biotherapeutics Products and Microbe CDMO Market, By Product
APIs
FDFs
Live Biotherapeutics Products and Microbe CDMO Market, By Type of Formulation
Solid Formulations
Oral Liquids
Injectables
Others
Live Biotherapeutics Products and Microbe CDMO Market, By Scale of Operation
Preclinical Scale Operations
Clinical Scale Operations
Commercial Scale Operations
Live Biotherapeutics Products and Microbe CDMO Market, By Region
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Live Biotherapeutics Products and Microbe CDMO Market.
Available Customizations:
Global Live Biotherapeutics Products and Microbe CDMO Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Live Biotherapeutics Products and Microbe CDMO Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Application (C.difficle, Crohns disease, IBS, Diabetes, Others)
5.2.2. By Product (APIs, FDFs)
5.2.3. By Type of Formulation (Solid Formulations, Oral Liquids, Injectables, Others)
5.2.4. By Scale of Operation (Preclinical Scale Operations, Clinical Scale Operations, Commercial Scale Operations)
5.2.5. By Region
5.2.6. By Company (2025)
5.3. Market Map
6. North America Live Biotherapeutics Products and Microbe CDMO Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Application
6.2.2. By Product
6.2.3. By Type of Formulation
6.2.4. By Scale of Operation
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Live Biotherapeutics Products and Microbe CDMO Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Application
6.3.1.2.2. By Product
6.3.1.2.3. By Type of Formulation
6.3.1.2.4. By Scale of Operation
6.3.2. Canada Live Biotherapeutics Products and Microbe CDMO Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Application
6.3.2.2.2. By Product
6.3.2.2.3. By Type of Formulation
6.3.2.2.4. By Scale of Operation
6.3.3. Mexico Live Biotherapeutics Products and Microbe CDMO Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Application
6.3.3.2.2. By Product
6.3.3.2.3. By Type of Formulation
6.3.3.2.4. By Scale of Operation
7. Europe Live Biotherapeutics Products and Microbe CDMO Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Application
7.2.2. By Product
7.2.3. By Type of Formulation
7.2.4. By Scale of Operation
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Live Biotherapeutics Products and Microbe CDMO Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Application
7.3.1.2.2. By Product
7.3.1.2.3. By Type of Formulation
7.3.1.2.4. By Scale of Operation
7.3.2. France Live Biotherapeutics Products and Microbe CDMO Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Application
7.3.2.2.2. By Product
7.3.2.2.3. By Type of Formulation
7.3.2.2.4. By Scale of Operation
7.3.3. United Kingdom Live Biotherapeutics Products and Microbe CDMO Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Application
7.3.3.2.2. By Product
7.3.3.2.3. By Type of Formulation
7.3.3.2.4. By Scale of Operation
7.3.4. Italy Live Biotherapeutics Products and Microbe CDMO Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Application
7.3.4.2.2. By Product
7.3.4.2.3. By Type of Formulation
7.3.4.2.4. By Scale of Operation
7.3.5. Spain Live Biotherapeutics Products and Microbe CDMO Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Application
7.3.5.2.2. By Product
7.3.5.2.3. By Type of Formulation
7.3.5.2.4. By Scale of Operation
8. Asia Pacific Live Biotherapeutics Products and Microbe CDMO Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Application
8.2.2. By Product
8.2.3. By Type of Formulation
8.2.4. By Scale of Operation
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Live Biotherapeutics Products and Microbe CDMO Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Application
8.3.1.2.2. By Product
8.3.1.2.3. By Type of Formulation
8.3.1.2.4. By Scale of Operation
8.3.2. India Live Biotherapeutics Products and Microbe CDMO Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Application
8.3.2.2.2. By Product
8.3.2.2.3. By Type of Formulation
8.3.2.2.4. By Scale of Operation
8.3.3. Japan Live Biotherapeutics Products and Microbe CDMO Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Application
8.3.3.2.2. By Product
8.3.3.2.3. By Type of Formulation
8.3.3.2.4. By Scale of Operation
8.3.4. South Korea Live Biotherapeutics Products and Microbe CDMO Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Application
8.3.4.2.2. By Product
8.3.4.2.3. By Type of Formulation
8.3.4.2.4. By Scale of Operation
8.3.5. Australia Live Biotherapeutics Products and Microbe CDMO Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Application
8.3.5.2.2. By Product
8.3.5.2.3. By Type of Formulation
8.3.5.2.4. By Scale of Operation
9. Middle East & Africa Live Biotherapeutics Products and Microbe CDMO Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Application
9.2.2. By Product
9.2.3. By Type of Formulation
9.2.4. By Scale of Operation
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Live Biotherapeutics Products and Microbe CDMO Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Application
9.3.1.2.2. By Product
9.3.1.2.3. By Type of Formulation
9.3.1.2.4. By Scale of Operation
9.3.2. UAE Live Biotherapeutics Products and Microbe CDMO Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Application
9.3.2.2.2. By Product
9.3.2.2.3. By Type of Formulation
9.3.2.2.4. By Scale of Operation
9.3.3. South Africa Live Biotherapeutics Products and Microbe CDMO Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Application
9.3.3.2.2. By Product
9.3.3.2.3. By Type of Formulation
9.3.3.2.4. By Scale of Operation
10. South America Live Biotherapeutics Products and Microbe CDMO Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Application
10.2.2. By Product
10.2.3. By Type of Formulation
10.2.4. By Scale of Operation
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Live Biotherapeutics Products and Microbe CDMO Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Application
10.3.1.2.2. By Product
10.3.1.2.3. By Type of Formulation
10.3.1.2.4. By Scale of Operation
10.3.2. Colombia Live Biotherapeutics Products and Microbe CDMO Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Application
10.3.2.2.2. By Product
10.3.2.2.3. By Type of Formulation
10.3.2.2.4. By Scale of Operation
10.3.3. Argentina Live Biotherapeutics Products and Microbe CDMO Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Application
10.3.3.2.2. By Product
10.3.3.2.3. By Type of Formulation
10.3.3.2.4. By Scale of Operation
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Live Biotherapeutics Products and Microbe CDMO Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Lonza Group Ltd.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Catalent, Inc.
15.3. Thermo Fisher Scientific Inc.
15.4. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
